The Landmark RCT - One-year results

Sponsored by Meril

Anchorperson: P. Serruys

Spokesperson: A. Baumbach

Summary

This session presents a detailed analysis of a landmark randomized controlled trial evaluating the Myval transcatheter aortic valve implantation (TAVI) system among other contemporary transcatheter valves. The discussion centers on one-year clinical outcomes, with a particular focus on women, patients with small aortic annuli, and those requiring permanent pacemaker implantation. Applying the updated VARC-3 criteria, the trial demonstrated that the Myval system is non-inferior to contemporary TAVI platforms in terms of clinical efficacy endpoints and survival. Hemodynamic performance was also comparable, with a lower incidence of moderate or severe regurgitation.

Learning Objectives

To gain deep understanding of VARC-3 recommendations on TAVI trials
To better understand the LANDMARK trial results: one-year follow-up
To learn about one-year results in specific cohorts - Women, small annuli, pacemaker dependency in patients with new PPI

Speaker

P. Serruys

Welcome and session objectives